نتایج جستجو برای: free treatment overall

تعداد نتایج: 2196605  

Journal: :Annals of the Academy of Medicine, Singapore 2012
Jin Yao Teo Puay Hoon Tan Wei Sean Yong

INTRODUCTION Male breast cancer is a rare disease entity, with little data from the Southeast Asian perspective. Hence, this study aims to review the data from our local experience in order to better delineate the disease characteristics in our population. MATERIALS AND METHODS Male patients with histologically proven breast cancer were identified from a prospectively collected database. The ...

Journal: :Molecular medicine reports 2008
Yuji Nakafusa Masayuki Tanaka Takao Ohtsuka Atsushi Miyoshi Naohiko Kohya Yoshihiko Kitajima Seiji Sato Sakiko Mochinaga Sawako Dohi Kohji Miyazaki

We conducted a Phase I/II study of combination therapy using CPT-11 and S-1 as a first-line treatment for metastatic colorectal cancer. The 28-day treatment cycle consisted of S-1 administered orally from day 1 to 21 and CPT-11 administered intravenously on days 1 and 15. In the Phase I portion, the dose of S-1 was fixed at 80 mg/m2/day, while CPT-11 was administered at a starting dose of 60 mg...

Journal: :The New England journal of medicine 2012
Martin Fassnacht Massimo Terzolo Bruno Allolio Eric Baudin Harm Haak Alfredo Berruti Staffan Welin Carmen Schade-Brittinger André Lacroix Barbara Jarzab Halfdan Sorbye David J Torpy Vinzenz Stepan David E Schteingart Wiebke Arlt Matthias Kroiss Sophie Leboulleux Paola Sperone Anders Sundin Ilse Hermsen Stefanie Hahner Holger S Willenberg Antoine Tabarin Marcus Quinkler Christelle de la Fouchardière Martin Schlumberger Franco Mantero Dirk Weismann Felix Beuschlein Hans Gelderblom Hanneke Wilmink Monica Sender Maureen Edgerly Werner Kenn Tito Fojo Hans-Helge Müller Britt Skogseid

BACKGROUND Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on da...

Journal: :Medical archives 2013
Hasan Mutlu Abdullah Büyükçelik Tuncay Aslan Abdülsamet Erden Zeki Akca

BACKGROUND Only 20% of patients with stage III NSCLC are cured by surgery. There is a disagreement among the oncologists in terms of whether which regimen (induction chemotherapy followed chemoradiotherapy, concurrent chemoradiation or concurrent chemoradiation followed consolidation chemotherapy) is best choice in inoperable LA NSCLC. OBJECTIVE To evaluate chemotherapy timing in inoperable L...

2013
Woncheol Choi Soomin An Eunmi Kwon Wankyu Eo Sanghun Lee

Background. Adenocarcinoma of the ampulla of Vater (AAV) is a rare malignancy that has a better prognosis than other periampullary cancers. However, the standard treatment for patients with relapsed or metastatic AAV has not been established. We investigated the clinical feasibility of standardized allergen-removed Rhus verniciflua stokes (aRVS) extract for advanced or metastatic AAV. Patients ...

2008
Bernard Nordlinger Halfdan Sorbye Bengt Glimelius Graeme J Poston Peter M Schlag Philippe Rougier Wolf O Bechstein John N Primrose Euan T Walpole Meg Finch-Jones Daniel Jaeck Darius Mirza Rowan W Parks Laurence Collette Michel Praet Ullrich Bethe Eric Van Cutsem Werner Scheithauer Thomas Gruenberger

BACKGROUND Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. METHODS This parallel-group study reports the trial's final dat...

2017
Hisao Imai Kyoichi Kaira Koichi Minato

Progression-free survival (PFS) and overall survival (OS) are two common endpoints in cancer trials. OS is usually preferred, because it is reliable, precise, meaningful, and can easily be documented. However, subsequent lines of therapy might confound the effects of first-line treatment on OS. Whether PFS or OS is the more appropriate endpoint in clinical trials of metastatic cancer remains co...

Journal: :Neuro-oncology 2016
Olivier L Chinot Ryo Nishikawa Warren Mason Roger Henriksson Frank Saran Timothy Cloughesy Josep Garcia Cedric Revil Lauren Abrey Wolfgang Wick

BACKGROUND In this post-hoc, exploratory analysis, we examined outcomes for patients enrolled in the AVAglio trial of front-line bevacizumab or placebo plus radiotherapy/temozolomide who received only a single line of therapy. METHODS Patients with newly diagnosed glioblastoma received protocol-defined treatment until progressive disease (PD). Co-primary endpoints were investigator-assessed p...

Journal: :European journal of cancer 1997
M E van der Burg G Bolis P J Bakker D Curran T Sahmoud J B Vermorken

In this study 22 patients with metastatic adenocarcinoma of the cervix were treated with a weekly bolus injection of 4'-epidoxorubicin at a dose of 12 mg/m2. Seventeen patients had received prior radiotherapy, all patients were chemo-naive. Toxicity was generally absent or very mild. One patient had a complete response and 2 patients had a partial response, one was an unconfirmed partial respon...

Journal: :Journal of the National Comprehensive Cancer Network : JNCCN 2006
M Rinaldi O Belvedere C Cauchi C Defferrari G Viola F Grossi

Recent trials have shown a benefit with maintenance therapy after 4 to 6 cycles of chemotherapy. These trials have shown improvement in progression-free survival using agents approved as second-line therapy in non-small cell lung cancer. Trials using erlotinib and pemetrexed showed improvement in overall survival. Consideration of trial design is critical for the interpretation of these results...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید